Logo image of CSBR

CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis

NASDAQ:CSBR - Nasdaq - US15870P3073 - Common Stock - Currency: USD

7.76  -0.04 (-0.51%)

Fundamental Rating

4

Overall CSBR gets a fundamental rating of 4 out of 10. We evaluated CSBR against 56 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of CSBR while its profitability can be described as average. CSBR has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

CSBR had positive earnings in the past year.
In the past year CSBR has reported a negative cash flow from operations.
In multiple years CSBR reported negative net income over the last 5 years.
In multiple years CSBR reported negative operating cash flow during the last 5 years.
CSBR Yearly Net Income VS EBIT VS OCF VS FCFCSBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

The Return On Assets of CSBR (20.98%) is better than 96.43% of its industry peers.
CSBR has a Return On Equity of 117.52%. This is amongst the best in the industry. CSBR outperforms 100.00% of its industry peers.
CSBR has a better Return On Invested Capital (49.38%) than 98.21% of its industry peers.
Industry RankSector Rank
ROA 20.98%
ROE 117.52%
ROIC 49.38%
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSBR Yearly ROA, ROE, ROICCSBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

CSBR has a better Profit Margin (10.97%) than 85.71% of its industry peers.
The Operating Margin of CSBR (11.48%) is better than 66.07% of its industry peers.
CSBR has a Gross Margin of 51.58%. This is comparable to the rest of the industry: CSBR outperforms 57.14% of its industry peers.
In the last couple of years the Gross Margin of CSBR has declined.
Industry RankSector Rank
OM 11.48%
PM (TTM) 10.97%
GM 51.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
CSBR Yearly Profit, Operating, Gross MarginsCSBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CSBR is creating value.
Compared to 1 year ago, CSBR has more shares outstanding
CSBR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CSBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CSBR Yearly Shares OutstandingCSBR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CSBR Yearly Total Debt VS Total AssetsCSBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of 1.64, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.64, CSBR perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
CSBR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CSBR has a Debt to Equity ratio of 0.02. This is in the better half of the industry: CSBR outperforms 67.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 1.64
ROIC/WACC4.69
WACC10.54%
CSBR Yearly LT Debt VS Equity VS FCFCSBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 0.99 indicates that CSBR may have some problems paying its short term obligations.
CSBR has a Current ratio of 0.99. This is amonst the worse of the industry: CSBR underperforms 85.71% of its industry peers.
CSBR has a Quick Ratio of 0.99. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
CSBR has a Quick ratio of 0.99. This is amonst the worse of the industry: CSBR underperforms 80.36% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.99
CSBR Yearly Current Assets VS Current LiabilitesCSBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 176.81% over the past year.
Looking at the last year, CSBR shows a quite strong growth in Revenue. The Revenue has grown by 19.03% in the last year.
CSBR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.13% yearly.
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%

3.2 Future

The Earnings Per Share is expected to grow by 56.78% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.84% on average over the next years. This is quite good.
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CSBR Yearly Revenue VS EstimatesCSBR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
CSBR Yearly EPS VS EstimatesCSBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 -0.4 -0.6

5

4. Valuation

4.1 Price/Earnings Ratio

CSBR is valuated correctly with a Price/Earnings ratio of 14.64.
91.07% of the companies in the same industry are more expensive than CSBR, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CSBR to the average of the S&P500 Index (27.18), we can say CSBR is valued slightly cheaper.
The Price/Forward Earnings ratio is 34.58, which means the current valuation is very expensive for CSBR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CSBR indicates a somewhat cheap valuation: CSBR is cheaper than 60.71% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CSBR to the average of the S&P500 Index (35.34), we can say CSBR is valued inline with the index average.
Industry RankSector Rank
PE 14.64
Fwd PE 34.58
CSBR Price Earnings VS Forward Price EarningsCSBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

91.07% of the companies in the same industry are more expensive than CSBR, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.45
CSBR Per share dataCSBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

CSBR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CSBR's earnings are expected to grow with 56.78% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y56.78%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CSBR!.
Industry RankSector Rank
Dividend Yield N/A

CHAMPIONS ONCOLOGY INC

NASDAQ:CSBR (7/16/2025, 1:02:20 PM)

7.76

-0.04 (-0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-12 2025-03-12/bmo
Earnings (Next)07-17 2025-07-17/amc
Inst Owners49.31%
Inst Owner Change0%
Ins Owners25.81%
Ins Owner Change0%
Market Cap107.32M
Analysts82.86
Price Target12.24 (57.73%)
Short Float %1.07%
Short Ratio3.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2009.8%
Min EPS beat(2)390.2%
Max EPS beat(2)3629.41%
EPS beat(4)4
Avg EPS beat(4)1146.3%
Min EPS beat(4)106.13%
Max EPS beat(4)3629.41%
EPS beat(8)5
Avg EPS beat(8)540.78%
EPS beat(12)6
Avg EPS beat(12)292.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.24%
Min Revenue beat(2)1.31%
Max Revenue beat(2)29.17%
Revenue beat(4)4
Avg Revenue beat(4)10.71%
Min Revenue beat(4)1.31%
Max Revenue beat(4)29.17%
Revenue beat(8)4
Avg Revenue beat(8)1.57%
Revenue beat(12)6
Avg Revenue beat(12)0.9%
Revenue beat(16)10
Avg Revenue beat(16)1.14%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 14.64
Fwd PE 34.58
P/S 1.83
P/FCF N/A
P/OCF N/A
P/B 19.62
P/tB 20.9
EV/EBITDA 12.45
EPS(TTM)0.53
EY6.83%
EPS(NY)0.22
Fwd EY2.89%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS4.24
BVpS0.4
TBVpS0.37
PEG (NY)0.09
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.98%
ROE 117.52%
ROCE 62.51%
ROIC 49.38%
ROICexc 70.31%
ROICexgc 73.57%
OM 11.48%
PM (TTM) 10.97%
GM 51.58%
FCFM N/A
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
F-Score5
Asset Turnover1.91
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.01
Cap/Depr 1.47%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.99
Altman-Z 1.64
F-Score5
WACC10.54%
ROIC/WACC4.69
Cap/Depr(3y)106.12%
Cap/Depr(5y)172.76%
Cap/Sales(3y)3.95%
Cap/Sales(5y)5.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
EBIT growth 1Y176.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.77%
OCF growth 3YN/A
OCF growth 5YN/A